Wordt geladen...
Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma
BACKGROUND: This phase I/II study aimed to determine the maximum tolerated dose (MTD) of nanoparticle albumin-bound paclitaxel (nab(®)-paclitaxel) plus cisplatin as treatment for metastatic nasopharyngeal carcinoma (NPC). METHODS: Patients were enrolled into 1 of 3 dose cohorts, each with 21-day tre...
Bewaard in:
| Gepubliceerd in: | BMC Cancer |
|---|---|
| Hoofdauteurs: | , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4944269/ https://ncbi.nlm.nih.gov/pubmed/27411683 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2517-5 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|